Menu Search
Equities

Regenerative Medical Technology Group Inc

RMTG:PKC

Regenerative Medical Technology Group Inc

Actions
  • Price (USD)0.0315
  • Today's Change0.005 / 17.98%
  • Shares traded12.33k
  • 1 Year change+140.46%
  • Beta1.1581
Data delayed at least 15 minutes, as of Nov 21 2024 14:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Regenerative Medical Technology Group Inc had net income fall 78.21% from a loss of 5.51m to a larger loss of 9.81m despite a 57.49% increase in revenues from 1.53m to 2.41m.
Gross margin68.95%
Net profit margin-353.35%
Operating margin-109.51%
Return on assets-191.67%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Regenerative Medical Technology Group Inc fell by 1.11m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 419.20k for operations while cash used for investing totalled 385.60k.
Cash flow per share-0.7854
Price/Cash flow per share--
Book value per share-2.07
Tangible book value per share-2.22
More ▼

Balance sheet in USDView more

Regenerative Medical Technology Group Inc uses little or no debt in its capital structure.
Current ratio0.026
Quick ratio0.0257
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.